Velafax pills 75mg №28

Indications and usage

 
Depression of various etiologies (treatment and prevention).

Contraindications

Hypersensitivity to the components of the drug Velafax;
simultaneous administration of MAO inhibitors; 
severe impaired renal and / or liver function (glomerular filtration rate, GFR less than 10 ml / min); 
age up to 18 years (safety and efficacy for patients in this age group have not been proven); 
established or suspected pregnancy; 
lactation period

Carefully Velafaks apply in the case of recent myocardial infarction, unstable angina, hypertension, tachycardia, convulsive syndrome history, elevated intraocular pressure, angle-closure glaucoma, manic state history, predisposition to bleeding, with initially reduced body weight.

Dosage and administration

Inside, while eating. The recommended initial daily dose of Velafax is 37.5 mg 2 times a day. If after several weeks of treatment there is no significant improvement, the dose of Velafax can be increased to 150 mg per day - 75 mg twice a day.

Adverse reactions

 
Common symptoms: weakness, fatigue.
On the part of the digestive tract: loss of appetite, constipation, nausea, vomiting, dry mouth, rarely - hepatitis. 
On the part of metabolism: an increase in serum cholesterol level, a decrease in body weight, sometimes - a change in the results of laboratory tests of liver function, hyponatremia, syndrome of insufficient secretion of antidiuretic hormone. 
Since the cardiovascular system: arterial hypertension, hyperemia of the skin, postural hypotension, tachycardia. 
From the side of the central nervous system: unusual dreams, dizziness, insomnia, irritability, paresthesia, stupor, increased muscle tone, tremor, yawning; sometimes apathy, hallucinations, muscle spasms, serotonin syndrome, rarely epileptic seizures, manic reactions, and symptoms resembling a neuroleptic malignant syndrome. 
On the part of the urogenital system: disturbances of ejaculation, erection, anorgasmia, dysuric disorders (mainly - difficulty at the beginning of urination); sometimes - decreased libido, menorrhagia, urinary retention. 
From the sense organs: accommodation disturbances, mydriasis, visual disturbances; infrequently - a violation of taste. 
On the part of the skin: sweating; sometimes - photosensitivity reactions; rarely - erythema multiforme, Stevens-Johnson syndrome. 
From the hemopoietic system: sometimes - hemorrhages into the skin (ecchymosis) and mucous membranes, thrombocytopenia; rarely, prolonged bleeding time.

Special notes

 
Withdrawal of Velafax: As with other antidepressants, abrupt cessation of venlafaxine therapy, especially after high doses of Velafax, may cause withdrawal symptoms, so it is recommended to gradually reduce the dose before discontinuing the drug. The duration of the period required to reduce the dose depends on its size, duration of therapy, as well as the individual sensitivity of the patient.

Storage conditions

Store Velafax in a dry, dark place at temperatures not higher than 25C.

 - 2 years.